All In Biotech

Drug Trial Radar · NCT05176483

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology or Other Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,394 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,394

Planned (sponsor's estimate)

Start

Dec 14, 2021

Primary completion

Jan 31, 2027

Study completion Jun 28, 2030

Sponsor

Lead sponsor
ExelixisIndustry
Sponsor type
Industry
First posted
Jan 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) and in combination with docetaxel and prednisone in participants with advanced solid tumors. In addition, the study will evaluate the effect of multiple dose administration of zanzalintinib on the single-dose pharmacokinetics of sensitive CYP3A4, CYP2C9, CYP2C19, or CYP1A2 substrates in participants with advanced solid tumors. In the Expansion Stage, the safety and efficacy of zanzalintinib as monotherapy and in combination therapy will be further evaluated in tumor-specific Expansion Cohorts.

Conditions

  • Renal Cell Carcinoma (RCC)
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Urothelial Carcinoma (UC)
  • Solid Tumor
  • Hepatocellular Carcinoma (HCC)
  • Non-small Cell Lung Cancer (NSCLC)
  • Colorectal Cancer (CRC)
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Clear Cell Renal Cell Carcinoma (ccRCC)
  • Non-Clear Cell Renal Cell Carcinoma (nccRCC)
  • Drug-Drug Interaction (DDI)

Interventions

  • ZanzalintinibDrug

    Zanzalintinib orally once daily (qd)

  • NivolumabDrug

    360 mg intravenous (IV) infusion once every 3 weeks (q3w)

  • IpilimumabDrug

    1 mg/kg IV infusion once every 3 weeks (q3w) for maximum of four doses

  • Nivolumab + RelatlimabDrug

    IV administration of nivolumab + relatlimab

  • PrednisoneDrug

    Administered as IV infusion.

  • DocetaxelDrug

    Administered as oral tablet.

  • DDI Probe CocktailDrug

    Midazolam, Warfarin, Omeprazole, and Caffeine administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Including Immune-Mediated Adverse Events (imAEs)Time frame: Up to 36 months
  2. Expansion Stage (All Cohorts Except Cohort 15 [mCRPC, post-ARPI, visceral metastases] and Cohort 16 [DDI]): Objective Response Rate (ORR)Time frame: Up to 24 months
  3. Expansion Stage Cohort 3 (mCRPC, post 1 NHT): Progression-Free Survival (PFS)Time frame: Up to 24 months
  4. Expansion Stage Cohort 10 (CRC): Overall Survival (OS)Time frame: 6 months
  5. Expansion Stage Cohort 15 (mCRPC, Post-ARPI, Visceral Metastases): PFS-6 (Six Month PFS)Time frame: 6 months
  6. Expansion Stage Cohort 16 (DDI): Area Under the Concentration-Versus-Time Curve (AUC) of Each DDI Probe Substrate With and Without ZanzalintinibTime frame: Predose upto 8 hours postdose
  7. Expansion Stage Cohort 16 (DDI): Maximum Concentration (Cmax) of Each DDI Probe Substrate With and Without ZanzalintinibTime frame: Predose upto 8 hours postdose

Locations

122 sites in 13 countries. Site status is shown where the registry gives one.

  • Exelixis Clinical Site #67

    Phoenix, Arizona · Recruiting

  • Exelixis Clinical Site #1

    Tucson, Arizona · Recruiting

  • Exelixis Clinical Site #123

    Palo Alto, California · Completed

  • Exelixis Clinical Site #59

    Santa Barbara, California · Recruiting

  • Exelixis Clinical Site #87

    Littleton, Colorado · Recruiting

  • Exelixis Clinical Site #62

    New Haven, Connecticut · Recruiting

  • Exelixis Clinical Site #49

    Newark, Delaware · Active not recruiting

  • Exelixis Clinical Site #48

    Celebration, Florida · Recruiting

  • Exelixis Clinical Site #11

    Gainesville, Florida · Recruiting

  • Exelixis Clinical Site #78

    Jacksonville, Florida · Recruiting

  • Exelixis Clinical Site #47

    Miami, Florida · Recruiting

  • Exelixis Clinical Site #61

    Plantation, Florida · Withdrawn

  • Exelixis Clinical Site #8

    Tampa, Florida · Recruiting

  • Exelixis Clinical Site #26

    Chicago, Illinois · Recruiting

  • Exelixis Clinical Site #4

    Indianapolis, Indiana · Recruiting

  • Exelixis Clinical Site #122

    Louisville, Kentucky · Withdrawn

  • Exelixis Clinical Site #14

    Baltimore, Maryland · Recruiting

  • Exelixis Clinical Site #7

    Boston, Massachusetts · Recruiting

  • Exelixis Clinical Site #65

    Detroit, Michigan · Recruiting

  • Exelixis Clinical Site #13

    Detroit, Michigan · Recruiting

  • Exelixis Clinical Site #68

    Rochester, Minnesota · Recruiting

  • Exelixis Clinical Site #2

    Omaha, Nebraska · Recruiting

  • Exelixis Clinical Site #5

    Omaha, Nebraska · Active not recruiting

  • Exelixis Clinical Site #55

    Las Vegas, Nevada · Recruiting

  • Exelixis Clinical Site #88

    East Brunswick, New Jersey · Recruiting

  • Exelixis Clinical Site #105

    Hackensack, New Jersey · Recruiting

  • Exelixis Clinical Site #60

    New York, New York · Recruiting

  • Exelixis Clinical Site #6

    New York, New York · Recruiting

  • Exelixis Clinical Site #76

    Syracuse, New York · Recruiting

  • Exelixis Clinical Site #12

    Durham, North Carolina · Recruiting

  • Exelixis Clinical Site #10

    Cleveland, Ohio · Recruiting

  • Exelixis Clinical Site #51

    Portland, Oregon · Recruiting

  • Exelixis Clinical Site #104

    Hershey, Pennsylvania · Recruiting

  • Exelixis Clinical Site #98

    Philadelphia, Pennsylvania · Recruiting

  • Exelixis Clinical Site #32

    Pittsburgh, Pennsylvania · Recruiting

  • Exelixis Clinical Site #24

    Pittsburgh, Pennsylvania · Completed

  • Exelixis Clinical Site #9

    Myrtle Beach, South Carolina · Recruiting

  • Exelixis Clinical Site #3

    Nashville, Tennessee · Recruiting

  • Exelixis Clinical Site #46

    Austin, Texas · Recruiting

  • Exelixis Clinical Site #111

    Dallas, Texas · Withdrawn

Showing 40 of 122 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.